Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue
+58.0%
EPS
+110.7%
Free cash flow
+411.2%
Total debt
−2.25%

Quarter to September 2026, against a year earlier

225.73 5.75 +2.61%
Market cap
$13.0B
P/E
0.0×
Fwd P/E
−803×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a

Glaukos Corporation (GKOS) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2016: revenue by regions, and margins
United States 105 91.78%
International 9 8.22%
Gross margin 85.86%
Operating margin 3.71%
Pre-tax margin 3.99%

Revenue by product or service $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
Glaucoma 421 303 237 214 232 179 231 181 159
Corneal Health 86 80 78 69 62 46 6 — —
Revenue 507 383 315 283 294 225 237 181 159

Revenue by segment $m

Line FY2025 FY2024 FY2023 FY2022
Development and Commercialization of Ophthalmic Therapies 507 383 315 283
Revenue 507 383 315 283

Gross profit by segment $m, and margin

Revenue by region $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013
United States 375 270 219 203 224 173 192 152 141 105 68 43 20
International 132 113 95 80 70 52 45 30 18 9 4 3 1
Revenue 507 383 315 283 294 225 237 181 159 114 72 46 21

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.